Interpolymer Complex of Chitosan and Eudragit L-100: Preparation, Characterization and Drug Release Behavior

Shrikant Bute\textsuperscript{a}, Saurabh Gupta\textsuperscript{b}, Kamlesh Wadher\textsuperscript{b}, Nikita Naidu\textsuperscript{b} and Milind Umekar\textsuperscript{b}

\textsuperscript{a} Department of Pharmaceutics, Smt Shantbai Patil Institute of Diploma in Pharmacy, India.
\textsuperscript{b} Department of Pharmaceutical Technology, Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur-441002, India.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

ABSTRACT

Aims: The aim of the present investigation was to prepare interpolymer complex between Chitosan and Eudragit L100, and to evaluate its performance as a matrix for controlled release of drugs, using Diclofenac sodium as a model.

Methodology: Interpolymer complex were prepared by combining different % chitosan solutions with different % Eudragit L100 solutions in different ratios. The formation of interpolyelectrolyte complexes (IPEC) between carbopol and Chitosan was investigated, using turbidimetry and viscosity measurement. The structure of the prepared IPEC was investigated using FTIR spectroscopy and DSC. A Rotary compression press was used to formulate matrix tablets of diclofenac sodium using polymers in physical mixture and IPECs. The amount of Diclofenac Sodium released in the dissolution medium was determined spectrophotometrically at 276 nm.

Results: The results of the present investigation confirmed the formation of an interpolyelectrolyte complex between Chitosan and Eudragit L 100. The release of the model drug Diclofenac sodium was significantly controlled from tablets made up of the IPEC as compared with polymers alone.

*Corresponding author: E-mail: kamleshwadher@gmail.com;
and in combination. Release profiles were represented by a mathematical model, which indicates that the prepared system releases drug in a zero-order manner by changing the ratio of the IPEC in the tablets.

**Conclusion:** Controlled release drug delivery systems designed to manipulate the drug release to achieve specific clinical objectives that are unattainable with conventional dosage forms.

**Keywords:** Interpolymer complex; diclofenac sodium; chitosan; eudragit; controlled release.

1. **INTRODUCTION**

Interpolyelectrolyte complexes (IPCs) are the products of non-covalent interactions between complementary unlike macromolecules in solutions. When oppositely charged polyelectrolytes are combined in solution, strong but reversible electrostatic connections emerge, which results in self-assembly or spontaneous association. IPCs networks will arise as a result of the direct interactions between the polymeric chains. There are several ways that can be utilised to broaden the scope of polymers used in dosage form design, such as modifying their chemical structure, combining different polymers in physical mixtures, or forming polymer-polymer interactions, such as interpolyelectrolyte complexes. Interpolyelectrolyte complexes combine the distinct physicochemical features of several polymers while maintaining good biocompatibility. As a result, IPCs are becoming more prevalent in modern pharmaceutical technology [1].

Polymer complexes are classified on the basis of its nature of association. Stereocomplexes, interpolyelectrolyte complexes, and hydrogen-bonded complexes are the three main types of polymer complexes. Interpolymer complexess are macromolecular structures generated by the non-covalent association of the polymers having affinity for each other. The complexes are insoluble and are generated by repeating units on different chains (interpolymer complexes) or on various portions of the same chain (subpolymer complexes) (intrapolymerncomplexes). They are well tolerated and are biocompatible but are very sensitive to the environmental changes [2,3].

Most polyamions and polycations readily produce IPECs. The ionic interaction of repeating units on polymer chains forms these complexes.

The formation and characterization of systems involving a variety of anionic and cationic polymers has increased in recent years due to an increasing interest in polyelectrolyte complexessuch as EudragitE 100-Eudragit L 100-55, chitosan–alginate/chitosan–carrageenan [4].

Many researchers have used different types of Eudragit for controlled drug delivery [5]. IPECs (interpolyelectrolyte complexes) are precipitates formed by combining cationic and anionic polymers in aqueous solutions. The advantages of IPEC as a polymeric carrier in controlled drug release systems are well known [6-8].

The media pH, ionic pressure, concentration, and, in certain cases, mixing order are all known to influence the stoichiometry of both components in IPEC. IPEC’s benefits as a polymeric carrier for drug release in regulated systems are well known [9].

The components that make up the IPEC can be chosen based on their properties, which are critical for its pharmaceutical application, such as incompatibility, pH-dependent solubility and swellability, and physicochemical stability. The purpose of this study was to investigate the formation of a novel IPEC between Chitosan (CH) and Eudragit L100 (EL) and to evaluate its performance as a matrix for controlled release of drugs, using Diclofenac sodium as a model.

2. **METHODOLOGY**

2.1 **Materials**

Diclofenac sodium was gifted from VamaPharma, Nagpur, India. Chitosan (Research Lab Fine Chemicals, Mumbai, India), Eudragit L100 (EvonikRoehmPharma, Mumbai). Sodium deoxycholate and microcrystalline cellulose purchased from loba chemicals, India. All the other chemicals and reagents used were of analytical grade.

2.2 **Method- Synthesis of Solid IPEC**

The IPEC of Chitosan(CS) and Eudragit L100 (EL) was prepared following the modified procedures given in literature [10,11]. Chitosan...
(0.5%) and Eudragit L100 (0.5%) solutions were made by dissolving them in acetic acid solution and 0.1 M NaOH, separately, then diluting them with demineralized water and adjusting the pH to 6.0. Chitosan and Eudragit L00 solutions were mixed at room temperature for 2 hours at pH 6.0, then vigorously agitated. By combining different volumes of % chitosans solutions with different volumes of % Eudragit L100 solutions in different ratios of 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2, and 9:1 respectively, nine different mixtures of solutions were formed. The mixture was then stirred continuously for 1 hour with a magnetic stirrer. The precipitate was washed with distilled water after being isolated by centrifugation at 6000 rpm. After that, the solid IPEC was dried for two days under vacuum at 50°C. The powder was sieved with an ass no. 80 sieve and used for further research.

3. PREPARATION OF TABLETS

A Rotary compression press was used to compress the IPEC powder (1:1) at 25 kg/cm² to produce flat faced tablets with a weight of 250 mg. Magnesium stearate (lubricant) and MCC (bulking agent) were added to the powder. The formula for preparation of tablets is given in Table 1.

4. EVALUATION OF IPEC

4.1 Physical Appearance

The physical appearance of IPEC complex was noted of all the batches prepared.

4.2 Turbidity Measurements

The Chitosan / Eudragit L100 ratio in the complex was examined by monitoring the transmittance of the solution at a wavelength of 600 nm using a spectrophotometer (Shimadzu Double Beam UV 2300 UV-Spectrophotometer).

4.3 Viscosity Measurements

The specific viscosity of the supernatant solution was determined by using a Brookfield viscometer.

4.4 pH Measurement

The pH of the solution was measured with a pH metre for each ratio. Chitosan and Eudragit were separately dispersed in acetic acid and the dispersion was stirred to form a uniform solution. Using NaOH solution, the pH of both the solution was adjusted to 6.

4.5 Infrared Spectroscopy

FTIR spectra of the prepared CH and EL solid IPEC, physical mixture, pure medication, and polymers were determined by Perkin Elmer, Norwalk, CT.

4.6 Differential Scanning Calorimetry (DSC)

Differential scanning calorimetry (DSC) study was carried out to evaluate thermal behavior and thermo tropic characteristics. It was carried out using a differential scanning calorimeter (Mettler Toledo DSC 822), in an aluminum-sealed tray, the samples were preheated to 200°C. The sample was cooled to room temperature before being reheated from 40° to 450° C at a rate of 10° C/min.

5. POST COMPRESSION EVALUATION OF SUSTAINED RELEASE TABLETS

5.1 Weight Variation

The weight variation test was done by weighing twenty tablets individually, calculating the average weight and then comparing the individual tablet weight to the average. The weight variation should be under the pharmacopeial limits.

5.2 Hardness

The hardness of the tablets was measured using Monsanto hardness tester. It is expressed in kg/cm².

5.3 Friability

Roche friabilator (Electrolab Friabilator – USP, Model No. EF-1W) was used to test the percent friability of the tablets. The weight lost should not exceed the limit 1.0%.

5.4 Thickness

The thickness of tablet was measured by using a digital calliper (ASAHI, India). Average values and SDs were determined using five tablets from each batch.

5.5 Determination of Drug Content

For the determination of drug 20 tablets were weighed and powdered. Powder equivalent to
50 mg of diclofenac sodium was weighed and taken in a volumetric flask, methanol was added up to 200 ml and shaken. About 5.0 ml of the solution was diluted to 100 ml with methanol and absorbance was measured at 285 nm.

### 5.6 Degree of Swelling of Tablets

The degree of swelling of tablets was determined in conditions that simulated the intestinal tract [12]. The volume of the medium was 40 ml, the tablets were taken out of the medium after every 15 minutes, dried with filter paper and measured. After 24 hours, a final weighing was done to determine the degree of swelling equilibrium. The swelling percentage (S%) was determined as follows:

\[
S_\% = \left( \frac{m_2 - m_1}{m_1} \right) \times 100
\]

Where, \( m_1 \) is the weight of the dry sample and \( m_2 \) is the weight of the swollen sample.

### 5.7 In-vitro Dissolution Studies of Sustained Release Tablet Formulations

The dissolution study of the tablets was carried out using the USP Apparatus-(Type II Paddle dissolution apparatus) (Electrolab Tablet Dissolution tester – USP, Model No. TDT – 06P) and used to release diclofenac sodium from matrix tablets at 37 ± 0.5°C. The pH of the release medium was maintained at 6.8, and aliquots (5 ml) of the solution were taken at predetermined time interval. Meanwhile, 5 ml of a fresh medium was used to replace the dissolution medium. The amount of Diclofenac Sodium released was measured spectrophotometrically at 276 nm with a spectrophotometer (Model No. UV 2300, Techcomp). The PCP DISSO – V3 software was used to measure the cumulative percent drug release and kinetics at various time intervals.

### 5.8 Determination of Release Mechanism

The release data obtained were treated according to zero-order, first-order, Higuchi and korsmeyer-Peppasequation models. To describe the kinetics of drug release from matrix tablets, release data was analyzed according to Kosmeyer et al’s equation [13-15] as,

\[
\frac{M_t}{M_\infty} = K t^n
\]

Where,

- \( M_t/M_\infty \) = fraction solute release
- \( t \) = release time
- \( K \) = kinetic constant characteristic of the drug/polymer system
- \( n \) = exponent that characterizes the mechanism of release of traces.

### 5.9 Tablet Surface Analysis

The tablet surface analysis was performed where the tablet samples were removed from the dissolution apparatus at the end of the dissolution test and the tablets were completely dried. The dried tablet was then seen through the Scanning Electron Microscope. The change in the tablet's surface was investigated.

### 6. RESULTS AND DISCUSSION

#### 6.1 Physical Appearance of IPEC Solution

There was distinct change in the physical appearance of the IPECs solution as shown in Fig. 1 and Table 2.

**Table 1. Preparation of Diclofenac sodium tablets using polymers and IPEC. (Drug:Polymer = 1:1)**

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>C1</th>
<th>C2</th>
<th>C3</th>
<th>C4</th>
<th>C5</th>
<th>C6</th>
<th>C7</th>
<th>C8</th>
<th>C9</th>
<th>C10</th>
<th>C11</th>
<th>C12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diclofenac sodium</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Chitosan</td>
<td>100</td>
<td>-</td>
<td>50</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Eudragit</td>
<td>-</td>
<td>100</td>
<td>50</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>L100</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>IPEC</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>47.5</td>
<td>47.5</td>
<td>47.5</td>
<td>47.5</td>
<td>47.5</td>
<td>47.5</td>
<td>47.5</td>
<td>47.5</td>
<td>47.5</td>
</tr>
<tr>
<td>MCC</td>
<td>47.5</td>
<td>47.5</td>
<td>47.5</td>
<td>47.5</td>
<td>47.5</td>
<td>47.5</td>
<td>47.5</td>
<td>47.5</td>
<td>47.5</td>
<td>47.5</td>
<td>47.5</td>
<td>47.5</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>2.5</td>
<td>2.5</td>
<td>2.5</td>
<td>2.5</td>
<td>2.5</td>
<td>2.5</td>
<td>2.5</td>
<td>2.5</td>
<td>2.5</td>
<td>2.5</td>
<td>2.5</td>
<td>2.5</td>
</tr>
</tbody>
</table>
Fig. 1. Physical appearance of the IPECs solution
Table 2. Physical appearance of the IPECs solution

<table>
<thead>
<tr>
<th>Chitosan: EudragitL100</th>
<th>Appearance without settling</th>
<th>Appearance after settling</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chitosan</td>
<td>Clear cream solution</td>
<td>Clear cream solution</td>
</tr>
<tr>
<td>Eudragit L100</td>
<td>Transparent solution</td>
<td>Transparent solution</td>
</tr>
<tr>
<td>10:90</td>
<td>White solution</td>
<td>White milky solution</td>
</tr>
<tr>
<td>20:80</td>
<td>White solution</td>
<td>White milky solution</td>
</tr>
<tr>
<td>30:70</td>
<td>White solution</td>
<td>White milky solution</td>
</tr>
<tr>
<td>40:60</td>
<td>White solution</td>
<td>Cream solution</td>
</tr>
<tr>
<td>50:50</td>
<td>White solution</td>
<td>White less milky solution</td>
</tr>
<tr>
<td>60:40</td>
<td>Cream solution</td>
<td>Milky cream solution</td>
</tr>
<tr>
<td>70:30</td>
<td>More creamy solution</td>
<td>Milky more cream solution</td>
</tr>
<tr>
<td>80:20</td>
<td>Yellowish solution</td>
<td>Yellowish turbid solution</td>
</tr>
<tr>
<td>90:10</td>
<td>More yellowish solution</td>
<td>Yellowish more turbid solution</td>
</tr>
</tbody>
</table>

6.2 Turbidity Measurements (% Transmittance of IPEC Solution)

The Chitosan / Eudragit L100 solution was filtered for examining the transmittance of the solution at a wavelength of 600 nm using a spectrophotometer and is depicted in Fig. 2.

Fig. 2 shows the percent transmittances of the solution and indicates the complete formation of IPEC; as the concentration of chitosan was increased, the solution's transmittance decreased; however, the transmittances of the IPEC 40:60 and 50:50 were found to be the highest, indicating that the reaction was complete and IPEC was formed in greater proportion. As a result, the percent transmittance of IPEC solution is directly proportional to formation of IPEC.

6.3 Viscosity of IPEC Solution

It was observed that the viscosity of IPEC solution increased as the concentration of Chitosan was increased. Fig. 3 represents the viscosity.

6.4 pH of Solution

The pH of the solution was determined before and after filtration using 0.5 percent (w/v) Chitosan and Eudragit L100 solutions in various ratios, resulting change in the pH of the solution during IPEC creation as shown in Fig. 4.
6.5 Infrared Spectrophotometry

The FTIR spectrum of Chitosan shows the absorption band at 1577 and 1656 cm\(^{-1}\) because of the amine group and at 3435 cm\(^{-1}\) due to the undissociated primary amino group (NH\(_2\)). Eudragit L100 shows a characteristic band at 1726 cm\(^{-1}\) because of the carboxylic acid. The IPECs showed the peak of amino groups of Chitosan and the peak of the carboxylic groups of Eudragit at 3435 cm\(^{-1}\) and at 1726 cm\(^{-1}\) respectively.

An additional peak of new band appeared at 1562 cm\(^{-1}\) because of the ionic interaction between the ionised carboxylic groups of Eudragit L100 and the protonated amino groups (–NH\(_3^+\)) of Chitosan. The binding ratio of the complex was stoichiometric, this finding seems to point to ionic bonding as a primary binding force in the complex formation between NH\(_3^+\) group of Chitosan and the COO\(^{-}\) group of Eudragit L100.

No significant difference was observed in IR spectrum, thus no interaction was found between the Diclofenac Sodium, Chitosan, Eudragit L100 and IPEC.

6.6 Differential Scanning Calorimetry (DSC)

Thermal analysis was carried out using a differential scanning calorimeter (Mettler Toledo DSC 822).

The DSC thermogram of pure Diclofenac Sodium showed a sharp endothermic peak at 287.3° C that shows the decomposition of drug. DSC thermogram of Eudragit L100 showed one exothermic peak and three endothermic peak, the small exothermic peak may be due to water loss at 143° C, followed by a glass transition temperature around 265.2° C with complete decomposition at 298.5° C characterized by 3rd endothermic peak in the thermogram. The pure Chitosan thermogram showed an exothermic peak at 311.2° C, attributable to the decomposition of Chitosan.

The DSC thermogram of Chitosan, Eudragit L100 and Diclofenac Sodium showed a characteristic peak where three endothermic peak were obtained at 235.25° C, 266.93° C, 291.78° C. DSC thermogram of IPEC 40:60 showed an endothermic peak at 244.1° C. The DSC thermogram of IPEC 40:60 and Diclofenac sodium showed two endothermic peak at 290.0° C and 316.86° C which indicates the presence of diclofenac Sodium. Therefore it is indicated that there is no reaction between drug and polymers.

7. POST-COMPRESSION ASSESSMENT OF SUSTAINED RELEASE TABLETS

7.1 Friability, Hardness, Thickness, Weight variation and Drug content

The friability of all the batches was found in the range of 0.246 to 0.489, which were found to pass the specified limits. Low values of friability indicate high resistance to abrasion and good binding property. The hardness of tablets was found in the range of 4.11 ± 0.125 to 8.44 ± 0.104 kg/cm\(^2\). The hardness of tablets can be attributed to presence of different ratio of IPEC.
The tablet thickness was found to be in the range of 3.73 ± 0.017 to 4.61 ± 0.053 mm.

The drug content was found to be more than 94.36%. The uniformity of active ingredients can be attributed to proper blending of ingredients prior to compression.

7.2 In-vitro Drug Release From Matrices

The amount of Diclofenac Sodium released in the dissolution medium was determined spectrophotometrically at 276 nm.

Matrices made up of chitosan C1 led to smaller drug release. In comparison to Chitosan the release of drug from the matrices made up of Eudragit L100 showed more sustain effect. The batch C2 and C3 showed 31.87% and 39.71% release of drug in 12 hr respectively.

IPEC 10:90 showed good sustain effect of around 24.02% release of drug. IPEC 20:80 matrices show release behaviour slower than that of the IPEC 10:90. This IPEC 20:80 can sustain the release more, with the more constant
drug release rate. IPEC 30:70 and 40:60 batch matrices show only 23.29% and 32.25% release of drug in 12 hr, which states that this batch has a good sustain effect as the concentration of IPEC is increased.

Batch 50:50, 60:40, 70:30, 80:20 and 90:10 showed the bursting effect and the complete release was shown in first 3 hours itself, this may be due to inability of polymer to form a coat over the drug particle.

Fig. 6. DSC Thermogram
Table 3. Shows the evaluated results of tablets for friability, hardness, thickness, weight variation, and drug content

<table>
<thead>
<tr>
<th>F. code</th>
<th>Friability* (%)</th>
<th>Hardness† (kg/cm³)</th>
<th>Thickness (mm)</th>
<th>Weight variation* (g)</th>
<th>Drug content*</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1</td>
<td>0.455 ± 0.09</td>
<td>5.96 ± 0.083</td>
<td>4.10 ± 0.025</td>
<td>0.25 ± 0.0077</td>
<td>99.8</td>
</tr>
<tr>
<td>C2</td>
<td>0.488 ± 0.03</td>
<td>0.454 ± 0.123</td>
<td>4.61 ± 0.053</td>
<td>0.25 ± 0.0079</td>
<td>98.6</td>
</tr>
<tr>
<td>C3</td>
<td>0.469 ± 0.02</td>
<td>4.48 ± 0.078</td>
<td>4.55 ± 0.036</td>
<td>0.252 ± 0.0059</td>
<td>97.2</td>
</tr>
<tr>
<td>C4</td>
<td>0.46 ± 0.07</td>
<td>5.22 ± 0.115</td>
<td>3.85 ± 0.036</td>
<td>0.25 ± 0.0077</td>
<td>95.1</td>
</tr>
<tr>
<td>C5</td>
<td>0.445 ± 0.03</td>
<td>4.56 ± 0.09</td>
<td>3.82 ± 0.031</td>
<td>0.249 ± 0.0061</td>
<td>100.1</td>
</tr>
<tr>
<td>C6</td>
<td>0.445 ± 0.27</td>
<td>6.19 ± 0.105</td>
<td>3.75 ± 0.032</td>
<td>0.246 ± 0.0063</td>
<td>99.3</td>
</tr>
<tr>
<td>C7</td>
<td>0.467 ± 0.03</td>
<td>5.11 ± 0.104</td>
<td>3.73 ± 0.017</td>
<td>0.245 ± 0.0058</td>
<td>96.98</td>
</tr>
<tr>
<td>C8</td>
<td>0.439 ± 0.17</td>
<td>5.79 ± 0.196</td>
<td>3.89 ± 0.035</td>
<td>0.251 ± 0.0087</td>
<td>94.36</td>
</tr>
<tr>
<td>C9</td>
<td>0.468 ± 0.04</td>
<td>5.11 ± 0.104</td>
<td>4.04 ± 0.055</td>
<td>0.249 ± 0.0099</td>
<td>97.28</td>
</tr>
<tr>
<td>C10</td>
<td>0.464 ± 0.05</td>
<td>6.19 ± 0.196</td>
<td>3.73 ± 0.025</td>
<td>0.25 ± 0.0082</td>
<td>94.79</td>
</tr>
<tr>
<td>C11</td>
<td>0.488 ± 0.06</td>
<td>5.87 ± 0.057</td>
<td>3.80 ± 0.015</td>
<td>0.251 ± 0.0078</td>
<td>97.54</td>
</tr>
<tr>
<td>C12</td>
<td>0.464 ± 0.06</td>
<td>6.19 ± 0.066</td>
<td>3.89 ± 0.031</td>
<td>0.25 ± 0.0071</td>
<td>99.06</td>
</tr>
</tbody>
</table>

Mean ± S.D. n=3, † n=6, * n=10

7.3 Kinetic Treatment of Data of Dissolution Profiles

Table 4 show the release kinetics of drug for individual polymers. The exponent of power law determines the probable mechanism by which drug has been released from the matrices. The release model was chosen on basis of best fitted criterion. Regression analysis of the equations determines the best fitted model. The other simplified form of the determination of release mechanism was proposed by Peppas et al. The exponential relation was utilized by these scientists to describe the Fickian and Non-Fickian release behavior of swelling controlled release systems.

It shows that the release kinetics is similar as earlier. However batch C6, C7, C8, C9, C10 and C11 follow Fickian diffusion (n = 0.1 to 0.5) and batch C1, C2, C3, C4, C5, and C12 follows Non-Fickian (n = 0. to 0.8) as projected by Korsmeyer-Peppas eq. The release of drug was found to be following Korsmeyer-Peppas eq. The value of exponent was 0.3434 which shows that it follows Non-Fickian as projected by Korsmeyer-Peppas eq.
Table 4. Release kinetics of formulations containing polymers and IPEC

<table>
<thead>
<tr>
<th>F.Code</th>
<th>Zero order</th>
<th>1st order</th>
<th>Matrix</th>
<th>Hix.Crow</th>
<th>Korsmeyer-Peppas</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>R</td>
<td>k</td>
<td>R</td>
<td>k</td>
<td>R</td>
</tr>
<tr>
<td>C1</td>
<td>0.872</td>
<td>4.586</td>
<td>0.933</td>
<td>-0.058</td>
<td>0.989</td>
</tr>
<tr>
<td>C2</td>
<td>0.717</td>
<td>3.341</td>
<td>0.773</td>
<td>-0.039</td>
<td>0.961</td>
</tr>
<tr>
<td>C3</td>
<td>0.919</td>
<td>3.410</td>
<td>0.955</td>
<td>-0.040</td>
<td>0.990</td>
</tr>
<tr>
<td>C4</td>
<td>0.958</td>
<td>2.130</td>
<td>0.971</td>
<td>-0.023</td>
<td>0.972</td>
</tr>
<tr>
<td>C5</td>
<td>0.887</td>
<td>2.314</td>
<td>0.910</td>
<td>-0.025</td>
<td>0.982</td>
</tr>
<tr>
<td>C6</td>
<td>0.903</td>
<td>2.216</td>
<td>0.921</td>
<td>-0.024</td>
<td>0.974</td>
</tr>
<tr>
<td>C7</td>
<td>0.795</td>
<td>3.040</td>
<td>0.855</td>
<td>-0.035</td>
<td>0.993</td>
</tr>
<tr>
<td>C8</td>
<td>0.859</td>
<td>16.35</td>
<td>0.895</td>
<td>-0.207</td>
<td>0.976</td>
</tr>
<tr>
<td>C9</td>
<td>0.864</td>
<td>16.759</td>
<td>0.900</td>
<td>-0.213</td>
<td>0.986</td>
</tr>
<tr>
<td>C10</td>
<td>0.881</td>
<td>16.84</td>
<td>0.918</td>
<td>-0.215</td>
<td>0.989</td>
</tr>
<tr>
<td>C11</td>
<td>0.868</td>
<td>16.586</td>
<td>0.904</td>
<td>-0.211</td>
<td>0.977</td>
</tr>
<tr>
<td>C12</td>
<td>0.871</td>
<td>16.636</td>
<td>0.906</td>
<td>-0.212</td>
<td>0.978</td>
</tr>
</tbody>
</table>
7.4 Tablet Surface Analysis

The SEM images of the tablet showing the surface morphology of before and after dissolution study are shown in Fig. 8. Fig. (a) shows intact surface without any channels or troughs. After dissolution, the solvent front enters the matrix and moves slowly toward the centre of the tablet through the pores as shown in Fig. (b). The drug diffuses out of the matrix after it comes in contact with dissolution medium. The drug release from the tablet is may be due to diffusion.

8. CONCLUSION

The results of the present investigation confirm the formation of an interpolyelectrolyte complex between Chitosan and Eudragit L 100. In the present work we found matrix tablet prepared by interpolymer complex of Ch and EL 100 provides extending drug release of Diclofenac sodium. The formulations showed good linearity which appears to indicate a coupling of diffusion and erosion mechanisms-so called anomalous diffusion.

ACKNOWLEDGMENTS

The authors are thankful to SmtKishoritaiBhoyar college of Pharmacy, Kamptee, Nagpur.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES


